{"transactions":[{"id":946262,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2026-01-06T21:05:23.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":111209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 111,209 shares were granted by the Issuer to the reporting Person for the 2025 annual dividend."}],"balance_after":439733,"source":{"system":"sec-edgar","filing":"0001429260-26-000004","document":"form4-01062026_040109.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000142926026000004/form4-01062026_040109.xml","form_type":"4"}},{"id":951062,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2026-01-05T21:30:31.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":278385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31.  278,385 shares were granted by the Issuer to the Reporting person for the 2025 annual dividend."}],"balance_after":536577,"source":{"system":"sec-edgar","filing":"0001429260-26-000002","document":"form4-01052026_040122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000142926026000002/form4-01052026_040122.xml","form_type":"4"}},{"id":1029209,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-10-01T20:05:38.000Z","date":"2025-09-29","kind":"grant","planned":false,"acquired":true,"shares":59334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer.  These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer."}],"balance_after":258192,"source":{"system":"sec-edgar","filing":"0001429260-25-000004","document":"form4-10012025_041032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000142926025000004/form4-10012025_041032.xml","form_type":"4"}},{"id":1124720,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"CLASS A COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-06-03T22:34:39.000Z","date":"2025-05-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation (\"Parent\"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub\").  On May 30, 2025 (the \"Closing Date\"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a \"CVR\"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Class A Common Stock had no expiration date and was convertible at any time at the option of Reporting Person into one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation (\"Parent\"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub\").  On May 30, 2025 (the \"Closing Date\"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a \"CVR\"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Class A Common Stock had no expiration date and was convertible at any time at the option of Reporting Person into one share of the Issuer's Common Stock."}],"balance_after":0,"derivative":{"exercise_price":4.1,"underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001415889-25-015470","document":"form4-06032025_100636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925015470/form4-06032025_100636.xml","form_type":"4"}},{"id":1124719,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-06-03T22:34:39.000Z","date":"2025-05-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6122249,"price":4.1,"value":25101220.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 9, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sun Pharmaceutical Industries, Inc., a Delaware corporation (\"Parent\"), and Snoopy Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Merger Sub\").  On May 30, 2025 (the \"Closing Date\"), Merger Sub merged with and into the Issuer pursuant to the Merger Agreement, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As a result of the Merger, each issued and outstanding share of Common Stock and Class A Common Stock that was previously held by the Reporting Person was automatically canceled and ceased to exist and was converted into the right to receive: (i) $4.10 in cash, without interest, and (ii) one non-tradable contingent value right (a \"CVR\"), which represents the right to receive a contingent cash payment of up to $0.70 upon the achievement of a specified milestone."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-015470","document":"form4-06032025_100636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925015470/form4-06032025_100636.xml","form_type":"4"}},{"id":1124718,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-06-03T22:34:39.000Z","date":"2025-05-29","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":1.29,"value":129000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 15, 2015, pursuant to the Fortress Biotech, Inc. Long Term Incentive Plan, the Reporting Person issued warrants to purchase 500,000 shares of Issuer common stock (out of the Reporting Person's holdings in the Issuer) to each of Lindsay A. Rosenwald and Michael S. Weiss (collectively, the \"Warrants\"). Following a December 2022 reverse stock split by the Issuer, the Warrants became exercisable into 100,000 shares of Issuer common stock in the aggregate, with an exercise price of $1.29 per share. Dr. Rosenwald and Mr. Weiss exercised the Warrants on May 29, 2025."}],"balance_after":6122249,"source":{"system":"sec-edgar","filing":"0001415889-25-015470","document":"form4-06032025_100636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925015470/form4-06032025_100636.xml","form_type":"4"}},{"id":1183173,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-04-02T20:05:14.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":67806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer.  These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer."}],"balance_after":198858,"source":{"system":"sec-edgar","filing":"0001415889-25-009620","document":"form4-04022025_040407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925009620/form4-04022025_040407.xml","form_type":"4"}},{"id":1183172,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-04-02T20:05:13.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":33724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer.  These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer."}],"balance_after":328524,"source":{"system":"sec-edgar","filing":"0001415889-25-009621","document":"form4-04022025_040409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925009621/form4-04022025_040409.xml","form_type":"4"}},{"id":1240525,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-02-27T21:25:08.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer.  These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer."}],"balance_after":6222249,"source":{"system":"sec-edgar","filing":"0001415889-25-005849","document":"form4-02272025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925005849/form4-02272025_040201.xml","form_type":"4"}},{"id":1314436,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-01-03T21:15:16.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":2386808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31.  These shares were granted by the Issuer to the Reporting Person for the 2024 annual equity fee grant."}],"balance_after":6203749,"source":{"system":"sec-edgar","filing":"0001415889-25-000403","document":"form4-01032025_040107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925000403/form4-01032025_040107.xml","form_type":"4"}},{"id":1314435,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2025-01-03T21:15:16.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":81407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer.  These shares were granted by the Issuer to the Reporting Person following the exercise of warrants."}],"balance_after":3816941,"source":{"system":"sec-edgar","filing":"0001415889-25-000403","document":"form4-01032025_040107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925000403/form4-01032025_040107.xml","form_type":"4"}},{"id":1396661,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-10-01T20:15:06.000Z","date":"2024-09-27","kind":"grant","planned":false,"acquired":true,"shares":146341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer.  These shares were granted by the Issuer to the Reporting Person following the closing of a financing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer.  These shares were granted by the Issuer to the Reporting Person following the closing of a financing."}],"balance_after":3735534,"source":{"system":"sec-edgar","filing":"0001415889-24-024182","document":"form4-10012024_041002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588924024182/form4-10012024_041002.xml","form_type":"4"}},{"id":1467138,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-06-28T20:22:34.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":575191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 575,191 shares were granted by the Issuer to the Reporting Person following the closing of equity financings."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 575,191 shares were granted by the Issuer to the Reporting Person following the closing of equity financings."}],"balance_after":2502991,"source":{"system":"sec-edgar","filing":"0001104659-24-076298","document":"tm2418561-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924076298/tm2418561-1_4seq1.xml","form_type":"4"}},{"id":1496608,"issuer":{"id":6273,"kind":"organization","name":"Journey Medical Corp"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-05-31T22:26:50.000Z","date":"2023-05-12","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer."}],"balance_after":3860467,"source":{"system":"sec-edgar","filing":"0001104659-24-067324","document":"tm2416203-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924067324/tm2416203-2_4seq1.xml","form_type":"4"}},{"id":1496607,"issuer":{"id":6273,"kind":"organization","name":"Journey Medical Corp"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-05-31T22:26:50.000Z","date":"2023-02-12","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer."}],"balance_after":3910467,"source":{"system":"sec-edgar","filing":"0001104659-24-067324","document":"tm2416203-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924067324/tm2416203-2_4seq1.xml","form_type":"4"}},{"id":1496606,"issuer":{"id":6273,"kind":"organization","name":"Journey Medical Corp"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-05-31T22:26:50.000Z","date":"2022-11-12","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer."}],"balance_after":3960467,"source":{"system":"sec-edgar","filing":"0001104659-24-067324","document":"tm2416203-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924067324/tm2416203-2_4seq1.xml","form_type":"4"}},{"id":1496605,"issuer":{"id":6273,"kind":"organization","name":"Journey Medical Corp"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-05-31T22:26:50.000Z","date":"2022-08-12","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer."}],"balance_after":4010467,"source":{"system":"sec-edgar","filing":"0001104659-24-067324","document":"tm2416203-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924067324/tm2416203-2_4seq1.xml","form_type":"4"}},{"id":1496604,"issuer":{"id":6273,"kind":"organization","name":"Journey Medical Corp"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-05-31T22:26:50.000Z","date":"2022-05-12","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transfer to employees of the Reporting Person as service grants in consideration of services provided to the Reporting Person and to Issuer."}],"balance_after":4060467,"source":{"system":"sec-edgar","filing":"0001104659-24-067324","document":"tm2416203-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924067324/tm2416203-2_4seq1.xml","form_type":"4"}},{"id":1539867,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-04-17T20:05:19.000Z","date":"2024-04-16","kind":"grant","planned":false,"acquired":true,"shares":413507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 413,507 shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":3547393,"source":{"system":"sec-edgar","filing":"0001104659-24-048303","document":"tm2412005-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924048303/tm2412005-1_4seq1.xml","form_type":"4"}},{"id":1563237,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-03-22T22:23:52.000Z","date":"2024-03-20","kind":"grant","planned":false,"acquired":true,"shares":193905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing."}],"balance_after":2096278,"source":{"system":"sec-edgar","filing":"0001104659-24-037986","document":"tm249605-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924037986/tm249605-2_4.xml","form_type":"4"}},{"id":1691990,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-01-03T21:29:43.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":419092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective April 3, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 66,003 shares were granted by the Issuer to the Reporting Person following the closing of equity financings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 353,089 shares were granted by the Issuer to the Reporting Person for the 2023 annual dividend."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective April 3, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."}],"balance_after":1927800,"source":{"system":"sec-edgar","filing":"0001104659-24-000859","document":"tm241755-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000859/tm241755-3_4seq1.xml","form_type":"4"}},{"id":1691989,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-01-03T21:28:57.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":158134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing."}],"balance_after":1902373,"source":{"system":"sec-edgar","filing":"0001104659-24-000856","document":"tm241755-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000856/tm241755-2_4seq1.xml","form_type":"4"}},{"id":1691988,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2024-01-03T21:27:48.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":2101496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 415,728 shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 1,685,768 shares were granted by the Issuer to the Reporting Person for the 2023 annual dividend."}],"balance_after":3133886,"source":{"system":"sec-edgar","filing":"0001104659-24-000853","document":"tm241755-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000853/tm241755-1_4seq1.xml","form_type":"4"}},{"id":1773283,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-09-26T20:16:17.000Z","date":"2023-09-25","kind":"grant","planned":false,"acquired":true,"shares":80906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing."}],"balance_after":1744239,"source":{"system":"sec-edgar","filing":"0001104659-23-103872","document":"tm2326953-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923103872/tm2326953-2_4seq1.xml","form_type":"4"}},{"id":1782866,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-09-12T13:02:05.000Z","date":"2023-09-08","kind":"purchase","planned":false,"acquired":true,"shares":418410,"price":0.72,"value":301255.2,"ownership":{"direct":true},"balance_after":1032390,"source":{"system":"sec-edgar","filing":"0001437749-23-025640","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000143774923025640/rdgdoc.xml","form_type":"4"}},{"id":1839562,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-07-03T17:15:21.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":81406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing."}],"balance_after":1663333,"source":{"system":"sec-edgar","filing":"0001104659-23-077533","document":"tm2320440d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923077533/tm2320440d1_4.xml","form_type":"4"}},{"id":1927808,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-04-04T20:08:05.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":52419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":613980,"source":{"system":"sec-edgar","filing":"0001104659-23-041491","document":"tm2311448-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923041491/tm2311448-2_4seq1.xml","form_type":"4"}},{"id":1927807,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-04-04T20:06:49.000Z","date":"2023-04-04","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing."}],"balance_after":1581927,"source":{"system":"sec-edgar","filing":"0001104659-23-041488","document":"tm2311448-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923041488/tm2311448-1_4seq1.xml","form_type":"4"}},{"id":1927806,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-04-04T20:06:49.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":35714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing."}],"balance_after":1539427,"source":{"system":"sec-edgar","filing":"0001104659-23-041488","document":"tm2311448-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923041488/tm2311448-1_4seq1.xml","form_type":"4"}},{"id":2060254,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-01-06T23:40:39.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":2807008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual dividend."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total number of shares beneficially owned by the Reporting Person includes those transactions as disclosed on the table filed herewith as Exhibit 99."}],"balance_after":22630620,"source":{"system":"sec-edgar","filing":"0001104659-23-001929","document":"tm232514-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923001929/tm232514-1_4seq1.xml","form_type":"4"}},{"id":2060253,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-01-06T22:57:20.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":368907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual equity fee grant."},{"field":"shares","element":"transactionShares","label":"F2","text":"Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The total number of shares beneficially owned by the Reporting Person includes those transactions as disclosed on the table filed herewith as Exhibit 99."}],"balance_after":1503713,"source":{"system":"sec-edgar","filing":"0001104659-23-001925","document":"tm232299-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923001925/tm232299-1_4seq1.xml","form_type":"4"}},{"id":2067004,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-01-04T22:49:03.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":231316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person is entitled to an annual dividend on its outstanding Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual dividend."},{"field":"shares","element":"transactionShares","label":"F4","text":"Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":561561,"source":{"system":"sec-edgar","filing":"0001104659-23-000998","document":"tm231707-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923000998/tm231707-1_4seq1.xml","form_type":"4"}},{"id":2067003,"issuer":{"id":8537,"kind":"organization","name":"AVENUE THERAPEUTICS, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.0001","published_at":"2023-01-04T22:49:03.000Z","date":"2022-12-31","kind":"grant","acquired":true,"shares":90909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."},{"field":"shares","element":"transactionShares","label":"F4","text":"Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":330245,"source":{"system":"sec-edgar","filing":"0001104659-23-000998","document":"tm231707-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923000998/tm231707-1_4seq1.xml","form_type":"4"}},{"id":4289727,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:43:24.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":1600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":10132653,"source":{"system":"sec-edgar","filing":"0001144204-17-031582","document":"v467961_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031582/v467961_form4.xml","form_type":"4"}},{"id":4289726,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:43:24.000Z","date":"2017-03-13","kind":"grant","acquired":true,"shares":767264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person is entitled to an annual dividend on its outstanding Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on March 13. These shares were granted by the Issuer to the Reporting Person for the 2017 annual dividend."}],"balance_after":10131053,"source":{"system":"sec-edgar","filing":"0001144204-17-031582","document":"v467961_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031582/v467961_form4.xml","form_type":"4"}},{"id":4289725,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:43:24.000Z","date":"2017-01-31","kind":"grant","acquired":true,"shares":213419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":9363789,"source":{"system":"sec-edgar","filing":"0001144204-17-031582","document":"v467961_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031582/v467961_form4.xml","form_type":"4"}},{"id":4289724,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:43:24.000Z","date":"2016-12-29","kind":"grant","acquired":true,"shares":15806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":9150370,"source":{"system":"sec-edgar","filing":"0001144204-17-031582","document":"v467961_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031582/v467961_form4.xml","form_type":"4"}},{"id":4289723,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:43:24.000Z","date":"2016-12-12","kind":"grant","acquired":true,"shares":11925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":9134564,"source":{"system":"sec-edgar","filing":"0001144204-17-031582","document":"v467961_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031582/v467961_form4.xml","form_type":"4"}},{"id":4289722,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:43:24.000Z","date":"2016-11-30","kind":"grant","acquired":true,"shares":47505,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":9122639,"source":{"system":"sec-edgar","filing":"0001144204-17-031582","document":"v467961_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031582/v467961_form4.xml","form_type":"4"}},{"id":4289721,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:43:24.000Z","date":"2016-10-25","kind":"grant","acquired":true,"shares":27264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":9075134,"source":{"system":"sec-edgar","filing":"0001144204-17-031582","document":"v467961_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031582/v467961_form4.xml","form_type":"4"}},{"id":4289720,"issuer":{"id":8350,"kind":"organization","name":"MUSTANG BIO, INC."},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:43:24.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":47870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing."}],"balance_after":9047870,"source":{"system":"sec-edgar","filing":"0001144204-17-031582","document":"v467961_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031582/v467961_form4.xml","form_type":"4"}},{"id":4289738,"issuer":{"id":78931,"kind":"organization","name":"Checkpoint Therapeutics, Inc.","symbol":"CKPT"},"owners":[{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc.","position":1,"cik":"0001429260","reported_name":"Fortress Biotech, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2017-06-07T21:31:49.000Z","date":"2017-03-17","kind":"grant","acquired":true,"shares":721699,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is entitled to an annual equity fee grant from the Issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on March 17. These shares were granted by the Issuer to the Reporting Person for the 2017 annual equity fee grant."}],"balance_after":2702705,"source":{"system":"sec-edgar","filing":"0001144204-17-031577","document":"v467959_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420417031577/v467959_form4.xml","form_type":"4"}}]}